Esmail El-Fakharany | Drug Delivery | Research Excellence Award

Published on by Research Chemistry Awards

Prof. Dr. Esmail El-Fakharany | Drug Delivery | Research Excellence Award

City of Scientific Research and Technological Applications | Egypt

Prof. Dr. Esmail El-Fakharany is a distinguished scientist affiliated with the Protein Research Department at the Genetic Engineering and Biotechnology Research Institute, City of Scientific Research and Technological Applications, where his work significantly advances biomedical and biotechnological research. He earned his Ph.D. in Microbiology with a minor specialization in biotechnology in 2012, following an M.Sc. in Microbiology with a focus on antiviral agents in 2009, both from the Faculty of Science, Al-Azhar University, Cairo. His academic foundation is further strengthened by a Diploma in Public Health Microbiology from the High Institute of Public Health, Alexandria University, and a B.Sc. in Microbiology with excellent distinction. Prof. Dr. El-Fakharany possesses extensive experience in immunology and immunoblotting, molecular biology, therapeutic protein and enzyme purification, antiviral and anticancer agent investigation, microbiological techniques, and tissue culture and cell line maintenance. His primary research interests center on antiviral proteins, recombinant and natural bioactive molecules, therapeutic protein engineering, immunological applications, and biotechnology-driven drug development. Through sustained scientific contributions, he has received professional recognition for excellence in microbiology and biotechnology research. Overall, his work continues to play a vital role in translating fundamental microbiological insights into innovative therapeutic strategies, contributing meaningfully to global health and applied life sciences.

View Google Scholar Profile

Featured Publications

Effectiveness of human, camel, bovine and sheep lactoferrin on the hepatitis C virus cellular infectivity: comparison study

Virology Journal, 2013, Vol. 10(1), Article 199

Oyster mushroom laccase inhibits hepatitis C virus entry into peripheral blood cells and hepatoma cells

Protein & Peptide Letters, 2010, Vol. 17(8), pp. 1031–1039

Examination of the activity of camel milk casein against hepatitis C virus (genotype-4a) and its apoptotic potential in hepatoma and HeLa cell lines

Hepatitis Monthly, 2011, Vol. 11(9)

Potential lactoferrin activity against pathogenic viruses

Comptes Rendus Biologies, 2014, Vol. 337(10), pp. 581–595

Poly(vinyl alcohol)–hyaluronic acid membranes for wound dressing applications: synthesis and in vitro bio-evaluations

Journal of the Brazilian Chemical Society, 2015, Vol. 26(7), pp. 1466–1474

Dr. Walmik Gaikwad | Conjugate Vaccines | Breakthrough Research Award

Published on by Research Chemistry Awards

Dr. Walmik Gaikwad | Conjugate Vaccines | Breakthrough Research Award

Inventprise Inc. Redmond, WA, US | United States

Dr. Walmik Gaikwad is a skilled biotechnologist and manufacturing leader with more than two decades of experience spanning academic research, industrial R&D, and large-scale vaccine production. He holds a Ph.D. in Chemical and Biotechnology from Savitribai Phule Pune University, where his doctoral work focused on developing conjugation processes for Streptococcus pneumoniae capsular polysaccharides with carrier proteins. He earned his M.Tech. in Biotechnology from Padmashree Dr. D. Y. Patil Institute for Biotechnology and Bioinformatics, specializing in bioremediation of phenolic compounds, and his B.Tech. in Chemical–Pharmaceutical and Fine Chemicals from Dr. Babasaheb Ambedkar Marathwada University, where he explored the synthesis of chromenone derivatives. Professionally, Dr. Gaikwad has led projects across upstream, downstream, and conjugation process development with extensive expertise in cGMP and GLP environments. His career includes key roles at Inventprise Inc., Redmond, where he currently manages vaccine manufacturing operations, and the Serum Institute of India, where he contributed significantly to multivalent conjugate vaccine R&D and production, regulatory audits, and technology transfer. His research interests lie in vaccine development, process optimization, and bioprocess scale-up under stringent quality frameworks. Recognized for his strategic leadership, regulatory acumen, and scientific rigor, Dr. Gaikwad continues to advance innovation in global vaccine manufacturing.

Profile: Google Scholar

Featured Publications

Simultaneous purification and depolymerization of Streptococcus pneumoniae serotype 2 capsular polysaccharides by trifluoroacetic acid

Purification of capsular polysaccharides isolated from S. pneumoniae serotype 2 by hydrogen peroxide and endonuclease

Effect of trifluoroacetic acid on the antigenicity of capsular polysaccharides obtained from various Streptococcus pneumoniae serotypes

Partial depolymerization of capsular polysaccharides isolated from Streptococcus pneumoniae serotype 2 by various methods

Methods for simultaneous fragmentation and purification of bacterial polysaccharides

Method for obtaining purified bacterial polysaccharides